A β-Cyclodextrin-Based Nanoparticle with Very High Transfection Efficiency Unveils siRNA-Activated TLR3 Responses in Human Prostate Cancer Cells

• Published in: Pharmaceutics Vol. 14; no. 11; p. 2424
• Main Authors: de la Torre, Cristina, Játiva, Pablo, Posadas, Inmaculada, Manzanares, Darío, Blanco, José L. Jiménez, Mellet, Carmen Ortiz, Fernández, José Manuel García, Ceña, Valentín
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-11-2022; MDPI
• Subjects: Androgens; Antimitotic agents; Antineoplastic agents; Cancer therapies; Cell growth; Chemical properties; Cyclodextrins; Dosage and administration; Drug delivery systems; Drug therapy; Drugs; FDA approval; Gene expression; glioblastoma; Health aspects; Kinases; Metastasis; Nanoparticles; p42-MAPK; Pharmaceutical research; Prostate cancer; Proteins; Rheb; Severe acute respiratory syndrome coronavirus 2; siRNA; TLR3; Transfection; Vaccines; Vehicles; β-cyclodextrin; Spain; United States > US
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics14112424

Synthetic double-stranded small interfering RNAs (siRNAs) mimic interference RNAs (RNAi) and can bind target mRNAs with a high degree of specificity, leading to selective knockdown of the proteins they encode. However, siRNAs are very labile and must be both protected and transported by nanoparticles to be efficiently delivered into cells. In this work, we used a Janus-type polycationic amphiphilic β-cyclodextrin derivative to efficiently transfect siRNAs targeting mRNAs encoding mitogen-activated protein kinase (p42-MAPK) or Ras homolog enriched in brain (Rheb) into different cancer cell lines as well as astrocytes. We took advantage of this high transfection efficiency to simultaneously knock down p42-MAPK and Rheb to boost docetaxel (DTX)-mediated toxicity in two human prostate cancer cell lines (LNCaP and PC3). We found that double knockdown of p42-MAPK and Rheb increased DTX-toxicity in LNCaP but not in PC3 cells. However, we also observed the same effect when scramble siRNA was used, therefore pointing to an off-target effect. Indeed, we found that the siRNA we used in this work induced toll-like receptor 3 activation, leading to β-interferon production and caspase activation. We believe that this mechanism could be very useful as a general strategy to elicit an immune response against prostate cancer cells.